Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback